Back to Authors

Mushtaq, Ammara

https://orcid.org/0000-0001-7945-3448

Mayo Clinic

Mayo Clinic

Citations 3

Correction for Schmidt-Malan et al., “ In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli”
Schmidt-Malan, Suzannah M., Mishra, Avisya J., Mushtaq, Ammara , Brinkman, Cassandra L., Patel, Robin , Patel, Robin

Antimicrobial Agents and Chemotherapy | January 28, 2019 | Volume: 63 | Issue: 2 | Pages: No page available

10.1128/aac.02563-18 Get It

In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli
Schmidt-Malan, Suzannah M., Mishra, Avisya J., Mushtaq, Ammara , Brinkman, Cassandra L., Patel, Robin , Patel, Robin

Antimicrobial Agents and Chemotherapy | May 15, 2018 | Volume: 62 | Issue: 8 | Pages: No page available

10.1128/aac.00533-18 Get It

Understanding which antimicrobial agents are likely to be active against Gram-negative bacilli can guide selection of antimicrobials for empirical therapy as mechanistic rapid diagnostics are adopted. In this study, we determined the MICs of a novel β-lactam–β-lactamase inhibitor combination, imipenem-relebactam, along with ceftolozane-tazobactam, imipenem, ertapenem, meropenem, ceftriaxone, and cefepime, against 282 drug-resistant isolates of Gram-negative bacilli.
Differential Antimicrobial Susceptibilities of Granulicatella adiacens and Abiotrophia defectiva
Mushtaq, Ammara , Greenwood‐Quaintance, Kerryl E. , Cole, Nicolynn C., Kohner, Peggy C., Ihde, Sherry M., Strand, Gregory J. , Harper, Lance W., Virk, Abinash, Patel, Robin , Virk, Abinash , Patel, Robin

Antimicrobial Agents and Chemotherapy | May 24, 2016 | Volume: 60 | Issue: 8 | Pages: 5036-5039

10.1128/aac.00485-16 Get It

ABSTRACT MICs of 25 Abiotrophia defectiva and 109 Granulicatella adiacens isolates were determined by broth microdilution. Using CLSI breakpoints, the susceptibilities of A. defectiva and G. adiacens isolates were, respectively, 24% and 34% to penicillin, 92% and 22% to ceftriaxone, 48% and 3% to cefepime, 72% and 87% to meropenem, 92% and 10% to cefotaxime, 100% and 97% to levofloxacin, 92% and 80% to clindamycin, and 24% and 50% to erythromycin. All isolates were susceptible to vancomycin. In the penicillin-susceptible subgroup, all A. defectiva isolates were susceptible to ceftriaxone; however, 62% of G. adiacens isolates were ceftriaxone nonsusceptible.